Anesthesia-Induced Oxidative Stress: Are There Differences between Intravenous and Inhaled Anesthetics?
Thomas SenonerCorinna Velik-SalchnerGünter LucknerHelmuth TauberPublished in: Oxidative medicine and cellular longevity (2021)
Agents used for the induction of anesthesia have been shown to either promote or mitigate oxidative stress. A fine balance between the presence of reactive oxygen species (ROS) and antioxidants is crucial for the proper normal functioning of the cell. A basal concentration of ROS is essential for the manifestation of cellular functions, whereas disproportionate levels of ROS cause damage to cellular macromolecules such as DNA, lipids, and proteins, eventually leading to necrosis and apoptosis. Increased ROS has been linked with numerous illnesses, such as cardiovascular, immune system, liver, and kidney, and has been shown to promote cancer and accelerate aging. Knowledge of the various pharmacologic agents that increase or reduce oxidative stress may promote a safer way of inducing anesthesia. Furthermore, surgery itself leads to increased ROS production and ischemia/reperfusion injury. Indeed, increased perioperative oxidative stress has been correlated with increased postoperative complications and prolonged recovery. Anesthesiologists care for patients during the whole spectrum of perioperative care and thus are in a unique position to deliver countermeasures to oxidative stress. Using preferentially an induction agent which reduces oxidative stress might lead to better clinical outcomes and fewer postoperative complications. Propofol has been shown in several studies to reduce oxidative stress, which reduces postoperative complications and leads to a faster recovery, and thus might represent the preferred induction agent in the right clinical setting.
Keyphrases
- oxidative stress
- dna damage
- reactive oxygen species
- ischemia reperfusion injury
- diabetic rats
- cell death
- induced apoptosis
- healthcare
- palliative care
- end stage renal disease
- newly diagnosed
- patients undergoing
- minimally invasive
- heat shock
- air pollution
- pain management
- cell therapy
- ejection fraction
- chronic kidney disease
- quality improvement
- nitric oxide
- prognostic factors
- single cell
- low dose
- coronary artery disease
- cell proliferation
- cardiac surgery
- cell cycle arrest
- coronary artery bypass
- single molecule
- cystic fibrosis
- papillary thyroid
- signaling pathway
- patient reported outcomes
- lymph node metastasis